DK1220913T3 - G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf - Google Patents

G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf

Info

Publication number
DK1220913T3
DK1220913T3 DK00967335T DK00967335T DK1220913T3 DK 1220913 T3 DK1220913 T3 DK 1220913T3 DK 00967335 T DK00967335 T DK 00967335T DK 00967335 T DK00967335 T DK 00967335T DK 1220913 T3 DK1220913 T3 DK 1220913T3
Authority
DK
Denmark
Prior art keywords
prostate cancer
phor
coupled receptor
regulated
prostate
Prior art date
Application number
DK00967335T
Other languages
Danish (da)
English (en)
Inventor
Arthur B Raitano
Daniel E H Afar
Aya Jakobovits
Mary Faris
Rene S Hubert
Douglas C Saffran
Steve C Mitchell
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DK1220913T3 publication Critical patent/DK1220913T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK00967335T 1999-10-05 2000-10-05 G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf DK1220913T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15790299P 1999-10-05 1999-10-05
PCT/US2000/027543 WO2001025434A1 (fr) 1999-10-05 2000-10-05 Recepteur couple a une proteine g regule positivement dans le cancer de la prostate et utilisation

Publications (1)

Publication Number Publication Date
DK1220913T3 true DK1220913T3 (da) 2009-03-16

Family

ID=22565799

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00967335T DK1220913T3 (da) 1999-10-05 2000-10-05 G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf
DK08165936.9T DK2003202T3 (da) 1999-10-05 2000-10-05 G-protein-koblet receptor opreguleret i prostatacancer og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08165936.9T DK2003202T3 (da) 1999-10-05 2000-10-05 G-protein-koblet receptor opreguleret i prostatacancer og anvendelser deraf

Country Status (13)

Country Link
EP (2) EP2003202B1 (fr)
JP (2) JP4272376B2 (fr)
AT (2) ATE524549T1 (fr)
AU (2) AU779685B2 (fr)
CA (1) CA2385032C (fr)
CY (2) CY1110059T1 (fr)
DE (1) DE60041073D1 (fr)
DK (2) DK1220913T3 (fr)
ES (2) ES2371212T3 (fr)
HK (1) HK1048494B (fr)
IL (1) IL147952A0 (fr)
PT (2) PT1220913E (fr)
WO (1) WO2001025434A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
IL158860A0 (en) * 2001-05-15 2004-05-12 Agensys Inc Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same
DK1864131T3 (da) * 2005-03-03 2011-10-31 Chemcom Sa Naturlig ligand af G protein koblet receptor RCC356 og anvendelser deraf
WO2007119515A1 (fr) * 2006-03-28 2007-10-25 Dainippon Sumitomo Pharma Co., Ltd. Nouveaux peptides antigènes tumoraux
JP2012196211A (ja) * 2012-04-10 2012-10-18 Japan Science & Technology Agency 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US4975287A (en) 1989-09-01 1990-12-04 Wm. Wrigley Jr. Company Gum composition containing protein macrocolloids
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ES2264239T3 (es) 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
WO1996002561A1 (fr) 1994-07-20 1996-02-01 The General Hospital Corporation Systemes de detection d'interactions entre proteines
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
EP0832122A4 (fr) 1995-06-05 1999-08-25 Human Genome Sciences Inc Recepteur hpraj70 de proteine g humaine
CA2252886C (fr) 1996-04-26 2008-02-12 Massachusetts Institute Of Technology Methode de criblage a l'aide de trois hybrides
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
ES2290964T3 (es) 1996-10-15 2008-02-16 The Regents Of The University Of California Modelos animales de la evolucion del cancer de prostata humano.
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
EP1000148A2 (fr) * 1997-08-01 2000-05-17 Genset Marqueurs sequences 5' exprimes pour proteines secretees exprimees dans la prostate
CN100419079C (zh) * 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
JP2003521870A (ja) * 1998-10-06 2003-07-22 インサイト・ファーマスーティカルズ・インコーポレイテッド Ｇタンパク質共役受容体タンパク質
WO2000020590A2 (fr) * 1998-10-06 2000-04-13 Incyte Pharmaceuticals, Inc. Proteines de recepteurs couples a des proteines g

Also Published As

Publication number Publication date
DE60041073D1 (de) 2009-01-22
EP1220913A1 (fr) 2002-07-10
PT1220913E (pt) 2009-02-16
ATE417104T1 (de) 2008-12-15
JP4272376B2 (ja) 2009-06-03
ES2316387T3 (es) 2009-04-16
EP2003202A2 (fr) 2008-12-17
AU7755300A (en) 2001-05-10
JP2009050256A (ja) 2009-03-12
EP2003202B1 (fr) 2011-09-14
AU779685B2 (en) 2005-02-03
ES2371212T3 (es) 2011-12-28
CY1110059T1 (el) 2015-01-14
AU2005201916A2 (en) 2005-08-25
CA2385032C (fr) 2013-12-10
HK1048494A1 (en) 2003-04-04
WO2001025434A1 (fr) 2001-04-12
AU2005201916B2 (en) 2008-06-19
IL147952A0 (en) 2002-08-14
HK1048494B (en) 2009-06-12
PT2003202E (pt) 2012-01-02
JP2003511029A (ja) 2003-03-25
AU2005201916A1 (en) 2005-06-02
JP4875671B2 (ja) 2012-02-15
CY1112202T1 (el) 2015-12-09
DK2003202T3 (da) 2012-01-16
ATE524549T1 (de) 2011-09-15
EP1220913B1 (fr) 2008-12-10
CA2385032A1 (fr) 2001-04-12
EP2003202A3 (fr) 2009-10-21

Similar Documents

Publication Publication Date Title
ES2202432T3 (es) Factor de crecimiento endotelial vascular b.
ATE478952T1 (de) 36p6d5: ausgeschiedenes tumorprotein
EP1488007A4 (fr) Profilage d'expression genique dans des tissus tumoraux ponctionnes
EP2444410A3 (fr) Polypeptides brachyury et procédés d'utilisation
TR200102577T2 (tr) Kanser Tedavisi için Casb616 Polipeptid ve Polinücleotidlerin kullanımı
SG145559A1 (en) Genes and polypeptides relating to human colon cancers
CY1112202T1 (el) Υποδοχεας συζευγμενος προς g πρωτεϊνη θετικως ρυθμισμενος σε καρκινο προστατη και χρησεις αυτου
CY1110029T1 (el) Γονιδιο που εκφραζεται στον καρκινο του προστατη
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE412412T1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs
Trieb et al. Effects of hyperthermia on heat shock protein expression, alkaline phosphatase activity and proliferation in human osteosarcoma cells
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
ATE425770T1 (de) Kontrastmittel
DE60035192D1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
ATE313647T1 (de) Dickdarm spezifische gene und proteine
WO2001090157A3 (fr) 98p7c3: proteine a homeodomaine fortement exprimee dans divers cancers
US6171818B1 (en) Protein having an anti-tumoral effect
WO2003025135A3 (fr) Genes associes a des tumeurs malignes
Hogen et al. EP008/# 378 Comparative genomic analysis of ovarian clear cell carcinoma patients with and without a second primary malignancy
AU2003247704A8 (en) Methods and compositions for diagnosing hepatocellular carcinoma
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
WO2002077234A3 (fr) Compositions et methodes se rapportant aux genes et aux proteines specifiques du colon
Carlson COX 2: a promising target for chemotherapy
EP1243653A3 (fr) Protéine E25a, procédés de production et utilization
Yang et al. Addition of systemic IL2 increases effectiveness of hu14. 18-IL2 immunocytokine therapy against NXS2 murine neuroblastoma